# Nicolas Escriou

List of Publications by Year
in descending order



| 43 | 9,004 | 186209 28 | 276775 41 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 48 | 48 | 48 | 13442 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein. Journal of Biological Chemistry, 2022, 298, 101290. | 1.6 | 16 |
| 2 | Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study. EBioMedicine, 2022, 75, 103810. | 2.7 | 17 |
| 3 | High seroprevalence but shortâ€lived immune response to SARSâ€CoVâ€2 infection in Paris. European Journal of Immunology, 2021, 51, 180-190. | 1.6 | 54 |
| 4 | Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. Cell Host and Microbe, 2021, 29, 236-249.e6. | 5.1 | 107 |
| 5 | Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance. Nature Communications, 2021, 12, 3025. | 5.8 | 66 |
| 6 | Low seroprevalence of COVID-19 in Lao PDR, late 2020. The Lancet Regional Health - Western Pacific, 2021, 13, 100197. | 1.3 | 13 |
| 7 | Nasopharyngeal and serological anti SARS-CoV-2 IgG/IgA responses in COVID-19 patients. Journal of Clinical Virology Plus, 2021, 1, 100041. | 0.4 | 9 |
| 8 | SARS-CoV-2 Natural Transmission from Human to Cat, Belgium, March 2020. Emerging Infectious Diseases, 2020, 26, 3069-3071. | 2.0 | 140 |
| 9 | A comparison of four serological assays for detecting antiâ€“SARS-CoV-2 antibodies in human serum samples from different populations. Science Translational Medicine, 2020, 12, . | 5.8 | 228 |
| 10 | Determinants Involved in Hepatitis C Virus and GB Virus B Primate Host Restriction. Journal of Virology, 2015, 89, 12131-12144. | 1.5 | 4 |
| 11 | Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity. Virology, 2015, 486, 134-145. | 1.1 | 30 |
| 12 | Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology, 2014, 452-453, 32-41. | 1.1 | 57 |
| 13 | Inhibition of Pyrimidine Biosynthesis Pathway Suppresses Viral Growth through Innate Immunity. PLoS Pathogens, 2013, 9, e1003678. | 2.1 | 137 |
| 14 | Kinetic Characterization of PB1-F2-Mediated Immunopathology during Highly Pathogenic Avian H5N1 Influenza Virus Infection. PLoS ONE, 2013, 8, e57894. | 1.1 | 41 |
| 15 | A Human Coronavirus Responsible for the Common Cold Massively Kills Dendritic Cells but Not Monocytes. Journal of Virology, 2012, 86, 7577-7587. | 1.5 | 117 |
| 16 | Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcÎ³R Pathway. Journal of Virology, 2011, 85, 10582-10597. | 1.5 | 294 |
| 17 | SUMOylation Promotes PML Degradation during Encephalomyocarditis Virus Infection. Journal of Virology, 2010, 84, 11634-11645. | 1.5 | 55 |
| 18 | Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity. Vaccine, 2010, 28, 3247-3256. | 1.7 | 39 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine. Cancer Immunology, Immunotherapy, 2008, 57, 1161-1171. | 2.0 | 5 |
| 20 | Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood, 2008, 112, 3713-3722. | 0.6 | 164 |
| 21 | Antigen Crosspresentation by Human Plasmacytoid Dendritic Cells. Immunity, 2007, 27, 481-492. | 6.6 | 248 |
| 22 | Codon conservation in the influenza A virus genome defines RNA packaging signals. Nucleic Acids Research, 2007, 35, 1897-1907. | 6.5 | 165 |
| 23 | Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS. Virology, 2007, 363, 288-302. | 1.1 | 17 |
| 24 | Recombinant influenza A viruses harboring optimized dicistronic NA segment with an extended native 5â€² terminal sequence: Induction of heterospecific B and T cell responses in mice. Virology, 2006, 345, 73-87. | 1.1 | 22 |
| 25 | Detrimental Contribution of the Toll-Like Receptor (TLR)3 to Influenza A Virusâ€“Induced Acute Pneumonia. PLoS Pathogens, 2006, 2, e53. | 2.1 | 447 |
| 26 | The generation of recombinant influenza A viruses expressing a PB2 fusion protein requires the conservation of a packaging signal overlapping the coding and noncoding regions at the 5â€² end of the PB2 segment. Virology, 2005, 341, 34-46. | 1.1 | 75 |
| 27 | Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E. Journal of General Virology, 2005, 86, 1423-1434. | 1.3 | 215 |
| 28 | Involvement of Toll-like Receptor 3 in the Immune Response of Lung Epithelial Cells to Double-stranded RNA and Influenza A Virus. Journal of Biological Chemistry, 2005, 280, 5571-5580. | 1.6 | 591 |
| 29 | Introduction of SARS in France, Marchâ€“April, 2003. Emerging Infectious Diseases, 2004, 10, 195-200. | 2.0 | 44 |
| 30 | Murine plasmacytoid dendritic cells induce effector/memory CD8+ T-cell responses in vivo after viral stimulation. Blood, 2004, 104, 1808-1815. | 0.6 | 116 |
| 31 | Expression of a foreign gene by stable recombinant influenza viruses harboring a dicistronic genomic segment with an internal promoter. Virology, 2003, 313, 235-249. | 1.1 | 25 |
| 32 | Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet, The, 2003, 362, 263-270. | 6.3 | 956 |
| 33 | Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. New England Journal of Medicine, 2003, 348, 1967-1976. | 13.9 | 3,971 |
| 34 | HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus. International Immunology, 2003, 15, 765-772. | 1.8 | 54 |
| 35 | Expression of a Membrane-Anchored Glycoprotein, the Influenza Virus Hemagglutinin, by Dicistronic Replicons Derived from the Poliovirus Genome. Journal of Virology, 2002, 76, 5285-5290. | 1.5 | 3 |
| 36 | Replicons from positive strand RNA viruses for naked RNA immunization against influenza. International Congress Series, 2001, 1219, 923-929. | 0.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Hemagglutinin residues of recent human A(H3N2) viruses that affect agglutination of chicken erythrocytes. International Congress Series, 2001, 1219, 369-374. | 0.2 | 3 |
| 38 | Hemagglutinin Residues of Recent Human A(H3N2) Influenza Viruses That Contribute to the Inability to Agglutinate Chicken Erythrocytes. Virology, 2001, 289, 74-85. | 1.1 | 140 |
| 39 | Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein. Journal of General Virology, 2001, 82, 1737-1747. | 1.3 | 37 |
| 40 | Genetic analysis of the compatibility between polymerase proteins from human and avian strains of influenza A viruses. Microbiology (United Kingdom), 2000, 81, 1283-1291. | 0.7 | 134 |
| 41 | Chronic intravenous injections of antigen induce and maintain tolerance in Tâ€‰cell receptor-transgenic mice. European Journal of Immunology, 1999, 29, 345-354. | 1.6 | 28 |
| 42 | Identification and Site-Directed Mutagenesis of the Primary (2A/2B) Cleavage Site of the Hepatitis A Virus Polyprotein: Functional Impact on the Infectivity of HAV RNA Transcripts. Virology, 1995, 213, 213-222. | 1.1 | 66 |
| 43 | Interleukin-1 and interleukin-6 synergize in preparing resting murine B cells to respond to anti-Î¼: Correlation with c-myc expression. Cellular Immunology, 1992, 141, 243-252. | 1.4 | 0 |